SCHEMBL3696383

SCHEMBL3696383

CCOC(=O)CN(CCc1ccc(S(N)(=O)=O)cc1)C(=O)CC1C(=O)N(CCc2ccc(Cl)cc2Cl)CC(=O)N1CCCN1CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APAF1 O14727 6/20 0.51
CASP3 P42574 6/20 0.51
CASP9 P55211 6/20 0.51
CYCS P99999 6/20 0.51
PTGS2 P35354 5/20 0.38
ACHE P22303 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
CA7 P43166 1/20 0.35
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
P2RX7 Q99572 1/20 0.34
F10 P00742 2/20 0.33
CCR4 P51679 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5956313 0.94 APAF1 (0.54) APAF1CASP3CASP9CYCSACHE
SCHEMBL3697423 0.92 APAF1 (0.52) APAF1CASP3CASP9CYCSACHE
SCHEMBL3695332 0.91 APAF1 (0.58) APAF1CASP3CASP9CYCSACHE
SCHEMBL5956320 0.91 APAF1 (0.51) APAF1CASP3CASP9CYCSACHE
SCHEMBL3701947 0.90 APAF1 (0.49) APAF1CASP3CASP9CYCSACHE
SCHEMBL3704029 0.89 APAF1 (0.54) APAF1CASP3CASP9CYCSACHE
SCHEMBL3700913 0.89 APAF1 (0.52) APAF1CASP3CASP9CYCSCCR4
SCHEMBL3708096 0.86 APAF1 (0.48) APAF1CASP3CASP9CYCSACHE
SCHEMBL3702484 0.86 APAF1 (0.53) APAF1CASP3CASP9CYCSACHE
SCHEMBL3705168 0.85 APAF1 (0.53) APAF1CASP3CASP9CYCSP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040701-B2 Apaf-1 inhibitor compounds LABORATORIOS SALVAT, S.A. (ES) 2015-05-26 US disclosed
US-9040701-B2 Apaf-1 inhibitor compounds LABORATORIOS SALVAT, S.A. (ES) 2015-05-26 US disclosed
US-9040701-B2 Apaf-1 inhibitor compounds LABORATORIOS SALVAT, S.A. (ES) 2015-05-26 US disclosed
US-20120122868-A1 APAF-1 INHIBITOR COMPOUNDS LABORATORIOS SALVAT, S.A. (ES) 2012-05-17 US disclosed
US-20120122868-A1 APAF-1 INHIBITOR COMPOUNDS LABORATORIOS SALVAT, S.A. (ES) 2012-05-17 US disclosed
US-20120122868-A1 APAF-1 INHIBITOR COMPOUNDS LABORATORIOS SALVAT, S.A. (ES) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122868-A1 APAF-1 INHIBITOR COMPOUNDS APAF1, API5, AIFM1 APAF1 1/4885CASP3 13/4885CASP9 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.